SD Biotechnologies에스디생명공학
217480 · KOSDAQ · ₩217480 · 에스디생명공학
₩499 ₩0 (0.00%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩30B | ₩34B | ₩47B | ₩93B | ₩125B |
| Cost of sales | ₩17B | ₩19B | ₩27B | ₩72B | ₩88B |
| Gross profit | ₩13B | ₩15B | ₩20B | ₩21B | ₩36B |
| Operating income | −₩6.3B | −₩9.2B | −₩14B | −₩41B | −₩35B |
| Net income | −₩7.5B | −₩15B | −₩6B | −₩75B | −₩45B |
| Net income to shareholders | −₩7.4B | −₩14B | −₩4.6B | −₩73B | −₩44B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩48B | ₩61B | ₩76B | ₩96B | ₩146B |
| Current assets | ₩43B | ₩46B | ₩59B | ₩44B | ₩80B |
| Cash and equivalents | ₩6.9B | ₩3.5B | ₩20B | ₩8B | ₩15B |
| Total liabilities | ₩18B | ₩31B | ₩31B | ₩92B | ₩97B |
| Current liabilities | ₩17B | ₩31B | ₩31B | ₩78B | ₩85B |
| Borrowings | ₩15B | ₩0 | ₩741M | ₩43B | ₩45B |
| Total equity | ₩30B | ₩30B | ₩45B | ₩4.8B | ₩49B |
| Shareholders' equity | ₩29B | ₩29B | ₩44B | ₩3.1B | ₩46B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩5.1B | −₩4.3B | −₩3.1B | −₩15B | −₩17B |
| Capital spending | ₩47M | ₩52M | ₩1B | ₩24B | ₩14B |
| Free cash flow | −₩5.2B | −₩4.3B | −₩4.1B | −₩39B | −₩32B |
Consolidated where available. Amounts in won.
Also known as: SD Biotechnologies / 에스디생명공학 / 217480 / KRX:217480
Source: KRX statistical information